Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04492488 · ClinicalTrials.gov registry record · Phase 1

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

A Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic Gastric Cancer, sponsored by Shanghai Miracogen.

Active
Registry status
Phase 1
Development phase
129
Enrollment target
2
Study locations

NCT04492488 is a Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic Gastric Cancer that is active but no longer recruiting, run by Shanghai Miracogen. The registered enrollment target is 129 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04492488, a Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic Gastric Cancer, is active but no longer recruiting, sponsored by Shanghai Miracogen.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
129 participants
Enrollment target
2
Study locations

Study Summary

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.

Conditions Studied

Advanced Solid Tumors Advanced or Metastatic Gastric Cancer Advanced or Metastatic Gastroesophageal Junction Cancer

Interventions

  • DRUG MRG002

Study Locations (2)

California

  • University of California Irvine Chao Family Comprehensive Cancer Center - Orange

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2021-05-24
Est. Completion 2024-12-31
Phase Phase 1

Sponsor

Shanghai Miracogen

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04492488

The ClinicalTrials.gov registry entry for NCT04492488 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (35% lower). The listed sponsor is Shanghai Miracogen, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which MRG002 is the first listed.

NCT04492488 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.

Frequently Asked Questions

What is clinical trial NCT04492488 about?

NCT04492488 is a clinical study titled "A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer". The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophag...

What is the current status of trial NCT04492488?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2021-05-24. Estimated completion is 2024-12-31.

What conditions does trial NCT04492488 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer.

What interventions are being tested in trial NCT04492488?

The interventions under investigation include: MRG002 (DRUG).

Who is sponsoring clinical trial NCT04492488?

This trial is sponsored by Shanghai Miracogen, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04492488 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Advanced or Metastatic Gastric Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.